A university spin-out is a company built to turn research into a product, and in 2026 the deal UK founders get for starting one is the best it has been in a decade.
The average equity stake a university takes has dropped to about 16%, down from 22 to 25% before the 2023 reforms, according to the Royal Academy of Engineering's Spotlight on Spinouts 2026. Founders keep more of their own company than they used to.
That matters because spin-outs are now where some of the UK's largest exits come from. Two of Europe's billion-dollar spin-out exits in 2025 came out of Oxford alone. This guide covers what a spin-out is, how much equity the university takes, how the deal is built, and how founders fund one.
What is a university spin-out?
A university spin-out is a company created to commercialise research, using intellectual property the university owns. The university licenses or assigns that IP to the new company and takes shares in return.
That shareholding is the line between a spin-out and an ordinary startup. A founder who starts a company from scratch owns all of it. A researcher who spins a discovery out of a university lab shares ownership with the institution that funded the work and holds the patents.
A spin-out is also different from licensing. A university can license its IP to an existing company for royalties and step back. A spin-out instead builds a new company around the research, with the academics often joining as founders. Spin-outs suit discoveries that need years of development and heavy investment, which is why they cluster in life sciences, deep tech and quantum rather than consumer apps.
How big is the UK spin-out scene in 2026?
UK university spin-outs are worth about £49 billion combined, a figure that has nearly tripled since 2020, according to the Royal Academy of Engineering. Around 2,000 have been created since 2010, and together they support roughly 27,000 jobs, 70% of them added since 2020.
The money has held up where other startup funding has not. Spin-outs raised £2.6 billion in 2024, up 38% on the year, even as wider UK venture funding fell, according to Beauhurst's spin-out investment research. That pattern runs against the wider market, where the picture is far more concentrated. Bizztor's own analysis of which UK cities and sectors win the most startup funding found London alone took 78% of what UK startups raised in 2026.
Geography is spreading. Oxford ranks first in Europe for spin-out value, with Cambridge, UCL, Bristol and Imperial also in the European top ten. Growth now shows up well beyond the Oxford, Cambridge and London triangle, in Manchester, Leeds, Liverpool, Sheffield, Nottingham, Dundee and Edinburgh.
The exits tell the same story. OrganOx, an Oxford liver-transplant device company, sold for about $1.5 billion in 2025, and Oxford Ionics, a quantum computing spin-out, was bought for around $1.1 billion. Smaller raises land every month, such as the Leeds spin-out adsilico's £10 million Series A to test medical devices on virtual patients.
How much equity does a university take in a spin-out?
Around 16% on average in 2026. That is the lowest figure in the decade the Royal Academy of Engineering has tracked, and down from 22 to 25% before 2023.
The change came from the government's Independent Review of University Spin-out Companies, published in November 2023, and the University Spin-out Investment Terms (USIT) guide that universities and investors wrote alongside it. The review recommended universities take 10 to 25% for IP-intensive spin-outs such as life sciences, and 10% or less for less IP-heavy ones such as software, where it said founders should keep the vast bulk of the equity.
The averages have moved, but not evenly. For deals struck in 2024 and 2025, life sciences spin-outs gave up about 20%, hardware about 14%, and software about 17%, which is still well above the 10% guidance.
For founders, the numbers are a negotiating tool. If a technology transfer office opens with a stake above its sector average, the published figures are a fair reference point to push back against. The guidance is a recommended band, not a rule, so not every office has moved to the average, and the figure is only a starting point. Vesting, anti-dilution rights and board control shape the deal as much as the headline percentage does.
How is a spin-out deal put together?
The deal starts with the technology transfer office, the university team that manages IP and decides what gets spun out. The office agrees how the patents move to the company, what shares the university takes, and what milestones or royalties attach to the licence.
Founder splits are rarely even. Among successful spin-outs, 63% ended up with unequal equity between co-founders and only 34% split it equally, so the question of who gets what is worth settling early and in writing.
Equity is only part of the agreement. Founder vesting decides how shares are earned over time, anti-dilution terms protect stakes through later rounds, and board rights decide who controls the company as it grows. A lower university stake does not help much if the other terms leave founders without a real say.
Spinning out is slow. Most companies take 12 to 18 months from decision to launch, and more than half of founders say team roles changed during that time. Research talent and company leadership are not always the same people.
How do you fund a university spin-out?
Spin-outs are usually funded by specialist deep tech and university investors rather than generalist seed funds, because the science takes longer to reach revenue. University venture funds, patient capital, angel syndicates and regional development bodies all play a part.
The capital often comes in larger, later rounds than a typical pre-seed startup would raise, matched to the cost of the science. London biotech Cytospire's £61 million Series A for cancer cell therapy is the scale deep tech can reach, while Glasgow's EnteroBiotix raised £19 million backed by the Scottish National Investment Bank for a microbiome trial. Regional programmes feed the pipeline too, such as Scottish Enterprise's High Growth Spinout Programme that backed SeaDyes, a seaweed-based textile dye startup, on its way to commercial spin-out.
UK tax relief also shapes who invests. The SEIS and EIS schemes give investors a large discount on their downside risk, which is part of why British angel money flows toward early, high-risk science at all.
What should founders weigh before spinning out?
The trade is support for ownership. A spin-out gives a founder access to patents, lab facilities, grant funding and a credible name, in exchange for a share of the company and a longer, more structured path to market.
For software, where the IP is lighter, the case for a spin-out is weaker now that the guidance pushes university stakes toward 10% or less. Some software founders are better off starting independently and licensing what they need.
For capital-intensive science, the spin-out route still makes sense, because few founders can fund years of lab work alone. The lower stakes of 2026, combined with £2.6 billion a year flowing into the sector, mean the terms are more in the founder's favour than at any point in the past decade. The researchers who understand both the science and the deal are the ones who keep the most of what they build.
